Sodium tanshinone IIA silate as an add-on therapy in patients with unstable angina pectoris.
Sodium tanshinone IIA silate as an add-on therapy in patients with unstable angina pectoris.
复制标题
DOI：
10.3978/j.issn.2072-1439.2014.12.37
复制
发表时间：
2014-12
影响因子：
2.5
通讯作者：
Haiyan Zhang;M. Long;Zhiwen Wu;Xu Han;Yichao Yu
中科院分区：
文献类型：
--
作者：
Haiyan Zhang;M. Long;Zhiwen Wu;Xu Han;Yichao Yu
目的探讨丹参酮IIA硅酸钠（STS）作为常规治疗的附加疗法是否可以为不稳定型心绞痛（UAP）患者提供额外的益处，并与血清炎症因子谱的变化有关。方法将80例确诊为UAP的患者随机分为两组，进行为期2周的治疗。对照组给予常规治疗，治疗组在常规药物治疗的基础上静脉注射STS （0.06 mg / 250 mL，每日1次）。比较两组患者的治疗效果和血清几种炎性细胞因子水平的变化，包括单核细胞趋化蛋白1 （MCP-1）、肿瘤坏死因子α (TNF-α)、过氧化物酶体增殖物激活受体（PPAR-γ）和高敏c反应蛋白（hs-CRP）。结果两组患者治疗后临床症状均有改善。治疗组总有效率为97.5%，对照组为80.0%。两组患者血清MCP-1、TNF-α和hs-CRP水平均显著降低（P<0.01），而额外接受STS治疗的患者血清MCP-1、TNF-α和hs-CRP水平降低更大（P<0.05）。两组PPAR-γ水平均显著升高（P<0.01）。结论：STS联合常规治疗可能与UAP患者更好的预后相关。
OBJECTIVE To investigate whether sodium tanshinone IIA silate (STS) as an add-on therapy to conventional treatment may provide additional benefits for patients with unstable angina pectoris (UAP) and is associated with changes in profiles of serum inflammatory factors. METHODS Eighty patients diagnosed with UAP were randomly divided into two groups for the 2-week treatment. The control group received conventional therapy, while the treatment group was given intravenous STS (0.06 mg in 250 mL, once daily) as an add-on therapy to the conventional medications. The therapeutic efficacy and changes in serum levels of several inflammatory cytokines, including monocyte chemotactic protein 1 (MCP-1), tumor necrosis factor alpha (TNF-α), peroxisome proliferator-activated receptor (PPAR-γ), and high-sensitivity C-reactive protein (hs-CRP) from baseline were determined and compared between the two group. RESULTS The clinical symptoms of all patients in both groups were improved after treatment. The overall rate of effectiveness was 97.5% in the treatment group vs. 80.0% in the control group. Serum levels of MCP-1, TNF-α, and hs-CRP levels were significantly reduced in both groups (P<0.01), whereas the reduction was greater in patients receiving additional STS (P<0.05). PPAR-γ was significantly elevated in both groups (P<0.01). CONCLUSIONS STS in combination with conventional treatment may be associated with better outcomes in patients with UAP.